← Leaderboards
Jason T Blackard
Cincinnati Childrens Hosp Med Ctr
$10,171,334
Attributed
$14,658,704
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,658,704 · 11
By mechanism
R01$9,702,206 · 5
R61$2,073,107 · 1
R33$1,220,730 · 1
R21$1,189,562 · 3
T35$473,099 · 1
Top collaborators
- Benjamin Lewis Laskin7 shared
- Jennifer L Brown4 shared
- Bingfang Yan4 shared
- Sonata Jodele2 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Sonata Jodele$3,229,150
- Benjamin Lewis Laskin$2,868,869
Others in their field
Top investigators on “Persons”
- Wafaa M. El-Sadr · Columbia University Health Sciences$688,439,560
- Lawrence Corey · Fred Hutchinson Cancer Center$646,462,796
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- David R. Weir · University Of Michigan At Ann Arbor$386,183,647
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$377,922,183
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$265,384,316
Research focus
PersonsMorbidity - Disease RateUniversitiesVirusViralMedicineMortalityIn VivoInfectionIn VitroCollegeHigh RiskPrevalenceVirus DiseasesDisease ProgressionImmune ResponseVirus ReplicationCohortSamplingProteinsAntiviral AgentsHiv InfectionsGenomePediatric Hospitals
Grant awards (35)
Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination$697,172
R01 · FY2025 · AA
Initiators of thrombotic microangiopathy$667,388
R01 · FY2025 · HL
Single cell opioid (fentanyl) responses in the context of HIV$587,188
R01 · FY2025 · DA · contact PI
Short-Term Institutional Research Training Grant$108,663
T35 · FY2025 · DK · contact PI
Initiators of thrombotic microangiopathy$706,638
R01 · FY2024 · HL
Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination$697,172
R01 · FY2024 · AA
Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis$647,714
R01 · FY2024 · DK
Short-Term Institutional Research Training Grant$97,173
T35 · FY2024 · DK · contact PI
Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination$697,172
R01 · FY2023 · AA
Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis$674,701
R01 · FY2023 · DK
Omics analysis of HIV during synthetic opioid exposure$604,585
R33 · FY2023 · DA · contact PI
Short-Term Institutional Research Training Grant$91,707
T35 · FY2023 · DK · contact PI
Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination$721,672
R01 · FY2022 · AA
Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis$674,701
R01 · FY2022 · DK
Omics analysis of HIV during synthetic opioid exposure$616,145
R33 · FY2022 · DA · contact PI
Short-Term Institutional Research Training Grant$90,312
T35 · FY2022 · DK · contact PI
Omics analysis of HIV during synthetic opioid exposure$741,485
R61 · FY2021 · DA · contact PI
Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis$674,701
R01 · FY2021 · DK
Short-Term Institutional Research Training Grant$85,244
T35 · FY2021 · DK · contact PI
Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis$719,972
R01 · FY2020 · DK
Omics analysis of HIV during synthetic opioid exposure$608,272
R61 · FY2020 · DA · contact PI
Omics analysis of HIV during synthetic opioid exposure$150,215
R61 · FY2020 · DA · contact PI
Omics analysis of HIV during synthetic opioid exposure$573,135
R61 · FY2019 · DA · contact PI
Genotypic& phenotypic characterization of the HCV polymerase (NS5B) in HIV$299,434
R01 · FY2017 · GM · contact PI
Genotypic& phenotypic characterization of the HCV polymerase (NS5B) in HIV$295,229
R01 · FY2016 · GM · contact PI
Genotypic& phenotypic characterization of the HCV polymerase (NS5B) in HIV$295,471
R01 · FY2015 · GM · contact PI
Genotypic& phenotypic characterization of the HCV polymerase (NS5B) in HIV$303,102
R01 · FY2014 · GM · contact PI
Genotypic& phenotypic characterization of the HCV polymerase (NS5B) in HIV$39,165
R01 · FY2014 · GM · contact PI
Genotypic& phenotypic characterization of the HCV polymerase (NS5B) in HIV$303,614
R01 · FY2013 · GM · contact PI
Occult Hepatitis B Infection in South African HIV Patients$190,194
R21 · FY2012 · AI · contact PI
Occult Hepatitis B Infection in South African HIV Patients$222,065
R21 · FY2011 · AI · contact PI
Clinical Relevance of GB Virus C & Hepatitis C Virus in HIV+ Women$194,288
R21 · FY2010 · AI · contact PI
Clinical Relevance of GB Virus C & Hepatitis C Virus in HIV+ Women$235,500
R21 · FY2009 · AI · contact PI
Extrahepatic Replication and Viral Evolution of HCV During HCV/HIV Co-infection$170,411
R21 · FY2007 · DA · contact PI
Extrahepatic Replication and Viral Evolution of HCV During HCV/HIV Co-infection$177,104
R21 · FY2006 · DA · contact PI